CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...

Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the ...

Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo.

Among patients with high-risk cutaneous squamous cell carcinoma (CSCC), postsurgical treatment with Libtayo (cemiplimab-rwlc) has been found to be associated with a similar rate of second primary ...

BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.